Merus Announces Annual Meeting of Shareholders
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, May 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V.
(Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that the Annual General
Meeting of Shareholders will be held on Wednesday, May 24, 2017 at 8:00 am CET,
at the Hilton Hotel Amsterdam Airport Schiphol, Schiphol Boulevard 701, 1118 BN
Schiphol, The Netherlands.
All relevant documents and information for the meeting, including the notice and
agenda, are available in the 'Investor Relations' section of Merus website
(www.merus.nl) under "Financial Information."
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe
as a potential treatment for HER2-expressing solid tumors. Merus' second
bispecific antibody candidate, MCLA-117, is being developed in a Phase 1
clinical trial in patients with acute myeloid leukemia. Merus also has a
pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem cells
and is being developed as a potential treatment for colorectal cancer and other
solid tumors, and Biclonics® designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
Forward Looking Statement
Except for the historical information set forth herein, this press release
contains predictions, estimates and other forward-looking statements, including
without limitation statements regarding the treatment potential of our
bispecific antibody candidates.
These forward-looking statements are based on management's current expectations.
These statements are neither promises nor guarantees, but involve known and
unknown risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-
looking statements, including, but not limited to, the following: potential
delays in regulatory approval, which would impact our ability to commercialize
our product candidates and affect our ability to generate revenue; the lengthy
and expensive process of clinical drug development, which has an uncertain
outcome; the unpredictable nature of our early stage development efforts for
marketable drugs; potential delays in enrollment of patients, which could affect
the receipt of necessary regulatory approvals; our reliance on third parties to
conduct our clinical trials and the potential for those third parties to not
perform satisfactorily; and our reliance on third parties to manufacture our
product candidates, which may delay, prevent or impair our development and
commercialization efforts.
These and other important factors discussed under the caption "Risk Factors" in
our Form 20-F filed with the Securities and Exchange Commission, or SEC, on
April 28, 2017, and our other reports filed with the SEC could cause actual
results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the future,
we disclaim any obligation to do so, even if subsequent events cause our views
to change, except as required under applicable law. These forward-looking
statements should not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 09.05.2017 - 15:41 Uhr
Sprache: Deutsch
News-ID 541250
Anzahl Zeichen: 5054
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus Announces Annual Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
